News from argen-x A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 10, 2014, 01:00 ET

arGEN-X and The Leukemia & Lymphoma Society Partner on the Development of ARGX-110 for the Treatment of Waldenström's Macroglobulinemia

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of...

Jun 04, 2014, 03:56 ET

ArGEN-X Enters Long-term Strategic Alliance With Shire Pharmaceuticals in Therapeutic Antibodies

  SIGNIFICANTLY EXPANDED RELATIONSHIP CREATED ON BACK OF COLLABORATION SUCCESS  arGEN-X, a clinical-stage biopharmaceutical company...

May 29, 2014, 04:00 ET

arGEN-X to Present Results of Phase 1 Study of ARGX-110, a Novel Anti-CD70 Antibody, in Patients With Advanced Cancer at ASCO

arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with...

May 28, 2014, 04:44 ET

arGEN-X Announces Collaboration with Bayer to Discover and Develop Therapeutic Antibody Candidates

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of...

Apr 07, 2014, 04:00 ET

arGEN-X Uses its Simple Antibody™ Platform to Identify Four 'Hotspots' on MET as Targets for its Therapeutic Antibody Program

New findings to be presented at the American Association for Cancer Research annual meeting  arGEN-X, a clinical stage human therapeutic...

Jan 13, 2014, 03:10 ET

arGEN-X Starts Phase Ib Expansion Cohorts With ARGX-110, a Novel Anti-CD70 Antibody, in Cancer Patients

Study supported by a €3.5 million IWT grant from the Flemish Government arGEN-X, a clinical stage human therapeutic antibody company,...

Jan 13, 2014, 03:09 ET

arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire

Enters into pilot research agreement with Boehringer Ingelheim arGEN-X, a clinical stage human therapeutic antibody company, announces the...

Dec 17, 2013, 03:00 ET

ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study

Dose confirmed for Phase Ib safety and efficacy expansion study arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead...

Nov 04, 2013, 03:00 ET

arGEN-X and de Duve Institute/UCL to Collaborate on Novel Immunomodulation Therapy in Cancer

arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement,...

Nov 04, 2013, 03:00 ET

arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B

Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards...

Sep 19, 2013, 03:00 ET

arGEN-X Reaches Milestone in Simple Antibody™ Research and Product Development Collaboration With Shire

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE...

Sep 17, 2013, 03:00 ET

arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer

SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumors arGEN-X, a clinical stage human monoclonal antibody...

Sep 12, 2013, 03:00 ET

arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7

- Breakthrough data to be presented during the 'Discovery on Target' conference in Boston, MA, USA on September 23, 2013 arGEN-X, a...

Aug 06, 2013, 04:06 ET

arGEN-X Grants Licenses to its NHance™ Antibody Half-Life Extension Technology

Meeting The Increasing Demand For Technologies That Enable Antibody Product Differentiation arGEN-X, a clinical stage biopharmaceutical company...

Apr 24, 2013, 07:26 ET

arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders

First program based on proprietary ABDEG™ technology to promote degradation and clearance of disease-causing autoantibodies arGEN-X, a...

Mar 25, 2013, 05:46 ET

arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology

ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation arGEN-X, a clinical stage biopharmaceutical company specialized in...

Jan 07, 2013, 03:00 ET

arGEN-X Initiates Phase Ib Study of ARGX-110 in Cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics,...

Jan 07, 2013, 03:00 ET

arGEN-X Expands its Therapeutic Antibody Alliance With Shire

New Discovery Program Initiated Within 12 Months Of Collaboration Start arGEN-X, a biopharmaceutical company specialized in the discovery and...

Oct 25, 2012, 04:31 ET

arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE...

Mar 19, 2012, 04:00 ET

Argen-X Launches NHance™ Technology to Generate Better Human Antibody Therapies

ADDS A SECOND PROPRIETARY TECHNOLOGY TO LEVERAGE THE POWER OF THE SIMPLE ANTIBODY™ PLATFORM   arGEN-X announces today the launch of...